Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1

INTRODUCTION: EVI1 (MECOM)-positive acute myeloid leukemia (AML) cells have shown in vitro sensitivity to all-trans-retinoic acid (ATRA) by inducing differentiation, cell death, and decreased leukemic engraftment. METHODS: In this pilot study, we investigated the response to ATRA in 13 high-risk AML...

Descripción completa

Detalles Bibliográficos
Autores principales: Paubelle, Etienne, Plesa, Adriana, Hayette, Sandrine, Elhamri, Mohamed, Zylbersztejn, Florence, Hermine, Olivier, Salles, Gilles, Thomas, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359977/
https://www.ncbi.nlm.nih.gov/pubmed/32699982
http://dx.doi.org/10.1007/s40487-019-0095-9
Descripción
Sumario:INTRODUCTION: EVI1 (MECOM)-positive acute myeloid leukemia (AML) cells have shown in vitro sensitivity to all-trans-retinoic acid (ATRA) by inducing differentiation, cell death, and decreased leukemic engraftment. METHODS: In this pilot study, we investigated the response to ATRA in 13 high-risk AML patients with overexpression of EVI1. RESULTS: Seven of the 13 patients (53.8%) achieved complete remission (CR), and response can be combined with a decreased of the leukemia stem cell pool. CONCLUSION: These primary results tend to confirm in vitro results and suggest that addition of ATRA might be of benefit in the treatment of patients with EVI1-positive AML.

Ejemplares similares